Frost & Sullivan Release: Robust New Technology Platforms Aid the Search for Cancer Vaccines

PALO ALTO, Calif.--(BUSINESS WIRE)--Although the cancer vaccine industry has remained historically undervalued due to its failures, optimism surrounds the industry as proponents of this technology have persistently pursued investigations to demonstrate the clinical efficacy of cancer vaccines. Cancer vaccines hold the potential to treat patients at an earlier stage of the disease, which sequentially generates therapies that will benefit the subset of population. In a metastatic disease setting, the trend would employ a cancer vaccine as an adjunct therapy with classical therapies such as chemotherapy, radiation therapy, and even with emerging therapies such as targeted therapies.